Abstract: A living-tissue normalization method and therapeutic device. The method includes intermittently flowing a slight direct current through a living body or living tissue at predetermined regular intervals to thereby activate a normalization mechanism of said living body or living tissue through the intermediary of protein. The therapeutic device includes a resistance provided between a pair of electrodes and current control arranged so that electrically conductive layers of a pair of pad elements are intermittently supplied with a slight direct current at predetermined regular intervals, and so that the pair of electrodes are supplied with a direct current.

Abstract: A living-tissue normalization method and therapeutic device. The method includes intermittently flowing a slight direct current through a living body or living tissue at predetermined regular intervals to thereby activate a normalization mechanism of said living body or living tissue through the intermediary of protein. The therapeutic device includes a resistance provided between a pair of electrodes and current control arranged so that electrically conductive layers of a pair of pad elements are intermittently supplied with a slight direct current at predetermined regular intervals, and so that the pair of electrodes are supplied with a direct current.

Abstract: A protein comprising the amino acid sequence set forth in SEQ ID NO: 1 in the Sequence Listing and a mutant thereof, possessing the glycoprotein production regulating activity, DNA comprising the nucleotide sequence set forth in SEQ ID NO: 2 in the Sequence Listing and a mutant thereof, as well as a therapeutic agent using any of the foregoing for the treatment of glycoprotein aberration disorders (e.g., cystic fibrosis), including gene therapy.